Structure Therapeutics shares hit a 52-week high after its weight loss drug showed 15.3% average weight loss in trials.

Structure Therapeutics Inc. shares jumped to a 52-week high of $94.90 after the company reported positive top-line results from a clinical trial of its experimental weight loss drug, aleniglipron. The once-daily oral medication, a GLP-1 receptor agonist, led to an average weight loss of 15.3%—about 35.5 pounds—in patients receiving a high dose, significantly more than placebo, with a favorable safety profile. The company plans to advance aleniglipron into Phase 3 trials, expected to start in mid-2026, following strong investor response and growing interest in novel obesity treatments.